DOCSLIB.ORG

Controlled, Multicenter, Parallel-Group Study to Assess the Safety and Efficacy of Tretinoin Gel Microsphere 0.04% in the Treatment of Acne Vulgaris in Adults

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Controlled, Multicenter, Parallel-Group Study to Assess the Safety and Efficacy of Tretinoin Gel Microsphere 0.04% in the Treatment of Acne Vulgaris in Adults THERAPEUTICS FOR THE CLINICIAN A Double-Blinded, Randomized, Vehicle- Controlled, Multicenter, Parallel-Group Study to Assess the Safety and Efficacy of Tretinoin Gel Microsphere 0.04% in the Treatment of Acne Vulgaris in Adults Richard Berger, MD; Alicia Barba, MD; Alan Fleischer, MD; James J. Leyden, MD; Anne Lucky, MD; David Pariser, MD; Elyse Rafal, MD; Diane Thiboutot, MD; David Wilson, MD; Rachel Grossman, MD; Marge Nighland, BS research grants from Johnson & Johnson and OrthoNeutrogena. Accepted for publication October 6, 2006. Dr. Thiboutot is an advisory board member and has participated in Dr. Berger is from Hill Top Research, Inc, East Brunswick, New clinical trials for CollaGenex Pharmaceuticals Inc; Connetics Jersey. Dr. Barba is from International Dermatology Research, Inc, Corporation; Dermik Laboratories; Galderma Laboratories, LP; Miami, Florida. Dr. Fleischer is from Wake Forest University School Intendis, Inc; Johnson & Johnson; and QLT Inc. She also is a of Medicine, Winston-Salem, North Carolina. Dr. Leyden is from consultant for CollaGenex Pharmaceuticals Inc; Intendis, Inc; KGL, Inc, Skin Study Center, Broomall, Pennsylvania. Dr. Lucky is and Stiefel Laboratories, Inc. Dr. Grossman and Ms. Nighland are from Dermatology Research Associates, Cincinnati, Ohio. employees of and receive executive compensation from Johnson Dr. Pariser is from the Department of Dermatology, Eastern & Johnson Consumer and Personal Products Worldwide. Virginia Medical School and Virginia Clinical Research, Inc, both Reprints: Marge Nighland, BS, Johnson & Johnson Consumer and in Norfolk. Dr. Rafal is from DermResearchCenter of New York, Personal Products Worldwide, 199 Grandview Rd, Skillman, NJ Stony Brook. Dr. Thiboutot is from Penn State Milton S. Hershey 08558-9418 (e-mail: [email protected]). Medical Center. Dr. Wilson is from The Education and Research Foundation, Lynchburg, Virginia. Dr. Grossman and Ms. Nighland are from Johnson & Johnson Consumer and Personal Products Worldwide, Skillman, New Jersey. This double-blinded, randomized, vehicle- Drs. Berger, Barba, Pariser, and Wilson report no conflict of inter- controlled, multicenter, parallel-group, 12-week, est. Dr. Fleischer is an advisory board member for Amgen Inc; phase 4 study was conducted in adults with mild Astellas Pharma Inc; and Galderma Laboratories, LP. He also is a to moderate acne vulgaris. Of 178 subjects ran- consultant for Astellas Pharma Inc; Combe Incorporated; domized to be treated, 88 subjects (49%) were Galderma Laboratories, LP; Gerson Lehrman Group; Intendis, Inc; Kikaku America International; Merz Pharma; and Warner Chilcott. treated with tretinoin gel microsphere 0.04% and Dr. Fleischer also is an investigator for 3M Pharmaceuticals; 90 subjects (51%) were treated with vehicle. Abbott Laboratories; Amgen Inc; Biogen Idec; Connetics Inflammatory lesion counts were statistically sig- Corporation; Coria Laboratories, Ltd; Dow Pharmaceutical nificantly reduced at 2 weeks in tretinoin-treated Sciences; Galderma Laboratories, LP; Genentech, Inc; subjects (P5.0110), and reductions in total lesion GlaxoSmithKline; Healthpoint, Ltd; Intendis, Inc; Medicis Pharmaceutical Corporation; Novartis Pharmaceuticals Corporation; counts also were noted. The reduction in total OrthoNeutrogena; and Pfizer Inc. He also is on the speakers lesion counts reached statistical significance at bureau for Amgen Inc; Astellas Pharma Inc; Connetics Corporation; week 4 (P5.0305); at week 12, mean total, inflam- Coria Laboratories, Ltd; Ferndale Laboratories, Inc; Galderma matory, and noninflammatory lesion counts were Laboratories, LP; Intendis, Inc; Medicis Pharmaceutical Corporation; statistically significantly lower in the tretinoin Novartis Pharmaceuticals Corporation; and Valeant Pharmaceuticals International. Dr. Leyden has conducted clinical trials for Ortho treatment group versus vehicle group (P,.05), Dermatologics. Dr. Lucky has conducted clinical trials for Johnson and mean percentage reductions in lesion counts & Johnson. Dr. Rafal has conducted clinical trials for and received were significantly greater in the subjects with 152 CUTIS® Therapeutics for the Clinician noninflammatory lesions treated with tretinoin protects tretinoin from photodegradation.9 Treti- compared with vehicle (P,.05). Mean percentage noin gel microsphere 0.1% and 0.04% markedly reductions in total, inflammatory, and noninflam- decreased noninflammatory lesion counts in vehicle- matory lesion counts were 35.5%, 38.2%, and controlled clinical trials10,11 and may result in a 33.6%, respectively, at week 12 for the tretinoin faster onset of action in the reduction of comedones treatment group compared with 20.9%, 19.2%, compared with adapalene, a synthetic polyaromatic and 20.4%, respectively, for the vehicle group retinoid.12 Tretinoin gel microsphere 0.1% dem- (all P,.05). All adverse events were of mild or onstrated a lower irritation profile compared with moderate intensity with the exception of severe tretinoin cream 0.1% in a half-face comparison skin irritation in one tretinoin-treated subject. At trial and a cumulative 21-day irritation evalua- week 12, there were no statistically significant tion.11 Because of the tolerability of the 0.04% differences between treatment groups for any formulation, the present study evaluated the safety measured tolerability parameter. and efficacy of tretinoin gel microsphere 0.04% Cutis. 2007;80:152-157. compared with vehicle. This is the first study of tretinoin for the treatment of acne in an exclusively adult population. n the United States, more than 4.5 million patients aged 25 to 44 years are affected by acne, Materials and Methods Iwhich represents 8% of adults aged 25 to 34 years Study Design and Participants—This was a double- and 3% of adults aged 35 to 44 years.1 Women espe- blinded, randomized, vehicle-controlled, multicenter, cially may continue to experience acne throughout parallel-group, 12-week, phase 4 study conducted in adulthood, up to and beyond 40 years of age, in some adults with acne vulgaris. The protocol was reviewed cases1; prevalence rates of 12% to 41% in women by the appropriate institutional review board at each older than 25 years have been reported.2,3 Premen- of the 9 participating study sites. strual acne flares are common.1 Subjects were between 19 and 45 years of age with In adults, inflammatory acne is more common mild to moderate acne vulgaris. To qualify for inclu- than comedonal acne. Also, the location of lesions sion, each subject had to have between 15 and 80 total in adults differ from the usual teenage pattern (ie, facial lesions that consisted of 10 to 40 inflammatory face, chest, back) and most commonly affect areas lesions and no more than 2 nodules. around the mouth, chin, and jawline.1 Late-onset Subjects were instructed to apply tretinoin gel acne in women may differ from acne that has per- microshere 0.04% to the face once nightly for sisted since adolescence because sebum secretion 12 consecutive weeks. A facial cleanser and mois- rates are higher in the latter group.4 turizer were supplied throughout the study period. Although a variety of topical and systemic A sunscreen with sun protection factor 30 was to agents are available, retinoids are the only topical be used during periods of extended UV exposure. antiacne agents believed to be effective against the Subjects were instructed not to apply moistur- microcomedone, which is the precursor lesion of izers or cosmetics to the face on the day of the acne.5,6 Tretinoin decreases abnormal keratinization, study evaluation. restores normal desquamation of follicular cells, Subjects were evaluated for safety and efficacy at facilitates comedolysis, and decreases the number baseline and after 2, 4, 8, and 12 weeks of therapy. of microcomedones.7 Early formulations of tretinoin At each visit, subjects were evaluated for inflamma- tended to cause excessive skin irritation because of tory lesions (papules and pustules), noninflammatory both the high concentration of active ingredient lesions (open and closed comedones combined), and and the hydroalcoholic vehicle. Topical formula- nodules. Safety evaluations included incidence and tions with lower concentrations of tretinoin and severity of adverse events, and signs and symptoms alternate vehicles are now available, but local skin of cutaneous irritation (ie, erythema, peeling, dry- irritation still may limit their use.8 ness, burning/stinging, and pruritus). Cutaneous Tretinoin gel microsphere is formulated with irritation was rated on a 4-point scale (05none, spongelike, porous, polymeric microspheres (polyol- 15mild, 25moderate, 35severe). prepolymer-2) that encapsulate the active ingredi- The primary efficacy end point was the percent- ent and serve as a reservoir. Tretinoin is released age change in total lesion counts from baseline to by the vehicle gradually, which potentially can week 12. In instances where an efficacy evaluation reduce irritation. The microsphere protects the was missing, the last available efficacy assessment degradation of tretinoin by peroxide and the deg- replaced the missing value. If no postbaseline radation of erythromycin by tretinoin, and also data were available, the baseline value was used. VOLUME 80, AUGUST 2007 153 Therapeutics for the Clinician Secondary end points included the change from Concomitant medications were coded using the baseline and percentage change from baseline World Health Organization drug glossary. The CMH in inflammatory and noninflammatory
Load more

Recommended publications
  • Preven Ng Pharmaceu Cal Pollu on and Diversion
    Preven&ng Pharmaceu&cal Pollu&on and Diversion Kate Hagemann & Sierra Fletcher Product Stewardship Ins&tute How to Participate Today • Open and close your Panel • View, Select, and Test your audio • Submit text questions • Raise your hand • Q&A addressed at the end of today’s session • Everyone will receive an email within 24 hours with a link to view a recorded version of today’s session Who is the Product Stewardship Instute? § Non-profit founded in 2000 § Membership ü 47 States ü 200+ Local governments ü 70+ Corporate, Organizaonal, Academic & Non-U.S. Government Partners § Board of Directors: 7 states, 4 local agencies • Mul4-stakeholder product stewardship network 3 The Problem: Waste Pharmaceucals 1. Environmental Concerns 2. Drug Diversion concerns 3. Public Safety Concerns 4 1. Environmental Concerns • Effects in the environment: – Endocrine disruptors – An&bio&c resistance • Pharmaceu&cals enter the environment via a number of channels – Agricultural run-off – Human excre&on – Improper disposal • Current waste water treatment plants cannot remove pharmaceu&cal compounds April 15, 2011 5 Evidence of pharmaceucals In our waterways • Minnesota Pollu&on Control Agency (2011) • USGS (June 2002) •“a broad range of chemicals found in residen3al, industrial, and agricultural wastewaters commonly occurs in mixtures at low concentra3ons downstream from areas of intense urbaniza3on and animal producon. The chemicals include human and veterinary drugs (including an3bio3cs), natural and synthe3c hormones, detergent metabolites, plas3cizers, inseccides, and fire retardants. One or more of these chemicals were found in 80 percent of the streams sampled” April 15, 2011 6 Environmental Impacts • Ecological impacts remain unknown • Observed impacts: – Abnormali&es – Disrupts reproduc&ve systems/risk of ex&ncon • Baylor University researchers found residues human medicaons in fish.
    [Show full text]
  • 38Th Annual Conference
    38th Annual Conference Conference Program Book Sponsored by: November 5-8, 2019 Booth #232 Salt Lake City, Utah Salt Palace Convention Center REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Committed to Patients Powered by Science Driven by Experience Amelia, CLN2 Jason, MPS II Charlie, HoFH Christopher, MPS I Geri, Wet AMD Our investigational gene therapy product candidates are designed to deliver genes to cells to address the genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. • 4 clinical stage programs in retinal, metabolic, and neurodegenerative diseases • Proprietary NAV® Technology Platform includes exclusive worldwide rights to over 100 AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 REGENXBIO.com Welcome to Salt Lake City! n behalf of the National Society of Genetic Counselors (NSGC), the Annual Conference Program Committee and the NSGC Board of O Directors, thank you for joining us! Table of Contents NSGC is excited to bring you education and networking opportunities Conference Information 5 designed to help you elevate the field of genetic counseling. Educational Schedule-at-a-Glance 8 sessions will cover a variety of topics at the forefront of genomics, such as gene editing, polygenic risk scores and artificial intelligence. Convention Center Map 13 Educational highlights you do not want to miss include: 40 years of the Reunion Information 14 Genetic Counseling Profession: A Foundation for the Future, The NSGC and ASHG Joint Session: Genetic Counselors in Research: From Dabbling Session Speakers + Objectives 16 in Clinic to an NIH Grant and the Professional Issues Panel.
    [Show full text]
  • Appendix 2 PCPSA Members Page 1 of 3 Companies Registered with PCPSA in 2008 Page: 2
    Companies registered with PCPSA in 2008 Page: 1 Company PCPSA Categories Registration Date AbbottTotals Laboratories Limited Brand Name November 8, 2006 Abraxis BioScience Inc. Generic December 4, 2006 Actelion Pharmaceuticals Canada Inc. Brand Name April 22, 2005 Advantage CKN Self-care June 22, 2001 Alcon Canada Inc. Brand Name March 7, 2007 Amgen Canada Inc. Brand Name March 9, 2007 Apotex Inc. Generic September 16, 2002 Astellas Pharma Canada Inc. Brand Name November 10, 2006 AstraZeneca Canada Inc. Brand Name December 14, 2001 Au Naturel Canada Inc. Self-care November 14, 2007 Axcan Pharma Inc. Brand Name April 6, 2005 Bayer Inc. Brand Name, Self-care February 5, 2004 Bioforce Canada Inc. Self-care August 27, 2007 Biovail Pharmaceuticals Canada Brand Name Boehringer Ingelheim Canada Ltd. Brand Name, Self-care July 21, 2004 Boiron Canada Inc. Self-care May 9, 2007 Bristol-Myers Squibb Pharmaceutical Group Brand Name, Self-care Canada Safeway Ltd. Self-care November 5, 2007 Chattem (Canada) Inc. Self-care April 23, 2004 Church & Dwight Canada Self-care August 14, 2001 Cobalt Pharmaceuticals Inc. Generic November 15, 2006 Combe Incorporated Self-care December 5, 2006 Costco Self-care CV Technologies Inc. Self-care October 26, 2006 Cytex Pharmaceutical Inc. Generic July 30, 2007 Eli Lilly Canada Inc. Brand Name September 9, 2001 EMD-Serono Canada Inc. Brand Name October 1, 2008 Enzymatic Therapy Self-care Ferring Inc. Brand Name Gaia Garden Herbals Inc. Self-care Galderma Canada Brand Name September 14, 2004 General Nutrition Centres Canada Self-care March 20, 2008 GenPharm Inc. Generic GlaxoSmithKline Consumer Healthcare Self-care August 30, 2001 GlaxoSmithKline Inc.
    [Show full text]
  • PCT Gazette, Weekly Issue No. 13, 2004
    13/2004 25 Mar/mar 2004 PCT Gazette - Section III - Gazette du PCT 7007 SECTION III WEEKLY INDEXES INDEX HEBDOMADAIRES INTERNATIONAL APPLICATION NUMBERS AND CORRESPONDING INTERNATIONAL PUBLICATION NUMBERS NUMÉROS DES DEMANDES INTERNATIONALES ET NUMÉROS DE PUBLICATION INTERNATIONALE CORRESPONDANTS International International International International International International Application Publication Application Publication Application Publication Numbers Numbers Numbers Numbers Numbers Numbers Numéros des Numéros de Numéros des Numéros de Numéros des Numéros de demandes publication demandes publication demandes publication internationales internationale internationales internationale internationales internationale AT BR CN PCT/AT2003/000079 WO 2004/025168 PCT/BR2003/000128 WO 2004/024058 PCT/CN2002/000705 WO 2004/025192 PCT/AT2003/000258 WO 2004/025667 PCT/CN2002/000801 WO 2004/024847 PCT/AT2003/000259 WO 2004/023943 CA PCT/CN2002/000879 WO 2004/025180 PCT/AT2003/000263 WO 2004/024605 PCT/CA2002/001381 WO 2004/024962 PCT/CN2003/000109 WO 2004/025932 PCT/AT2003/000265 WO 2004/023919 PCT/CA2002/001393 WO 2004/024545 PCT/CN2003/000198 WO 2004/025681 PCT/AT2003/000266 WO 2004/025573 PCT/CA2003/000362 WO 2004/024553 PCT/CN2003/000252 WO 2004/025605 PCT/AT2003/000267 WO 2004/025574 PCT/CA2003/001152 WO 2004/024412 PCT/CN2003/000278 WO 2004/025064 PCT/AT2003/000271 WO 2004/024020 PCT/CA2003/001187 WO 2004/024574 PCT/CN2003/000500 WO 2004/024724 PCT/AT2003/000272 WO 2004/024529 PCT/CA2003/001290 WO 2004/024419 PCT/CN2003/000502 WO 2004/024678
    [Show full text]
  • Product Stewardship Financing Models: a Look at the Post-Consumer Product Stewardship Association
    Product Stewardship Financing Models: A Look at the Post-Consumer Product Stewardship Association Type of Brand-owner funded take-back program (mandatory in BC and Manitoba). Program: Pharmaceuticals and natural health products, including prescription drugs, nonprescription Scope: medicines and natural health products such as herbal products, mineral and vitamin supplements (accepted in household quantities). In 1997, the B.C. Waste Management Act – Post Consumer Residual Stewardship, required all Status: brand-owners of pharmaceutical products to be responsible for their products’ end-of-life disposal. Starting in 2000, PCPSA began managing the stewardship plan with the Medications Return Program. The Recycling Regulation (B.C. Reg 449/2004) has now replaced the previous regulation. Overview Unused medications are a health and safety hazard when stored in patients’ homes. They can also damage the natural environment when incorrectly used or disposed of. The Post-Consumer Pharmaceutical Stewardship Association (PCPSA) is a non-profit organization that directly administers the Medications Return Program through funding from pharmaceutical and consumer health products members. PCPSA was established by the industry to comply with British Columbia’s Waste Management Act, a law intended to reduce the environmental and public health risks associated with consumer goods, including leftover medications. The act requires producers to establish a system to safely collect and dispose of the public’s unused medications. PCPSA has been successfully administering the program since 2000 and now represents over 140 pharmaceutical and consumer health products brand-owners (see the final page for a full listing). While these programs are regulated in British Columbia and Manitoba similar programs are run on a voluntary basis in other provinces and territories The program has been extremely successful in gaining the support and participation of community pharmacies.
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]
  • Pharmaceuticals and Product Stewardship
    Pharmaceuticals and Product Stewardship Sierra Fletcher Product Stewardship Institute April 29, 2011 Who is the Product Stewardship Institute? . Non‐profit founded in 2000 . Membership 47 States 200+ Local governments 70+ Corporate, Organizational, Academic & Non‐U.S. Government Partners . Board of Directors: 7 states, 4 local agencies • Multi‐stakeholder product stewardship network April 29, 2011 2 Product Stewardship : councils & other groups promoting product stewardship April 29, 2011 3 Why do we need it? The average American throws away 1,600 pounds of trash each year That means by age 25 you’ve thrown away 40,000 pounds Different Kinds of Toxicity April 29, 2011 5 We are all responsible… Shared Responsibility Manufacturers Retailers Other Businesses Government Consumers April 29, 2011 6 PSI Principles of Product Stewardship 1. Cost internalization 2. Shared responsibility (manufacturers have greatest role) 3. Lifecycle costs 4. Performance goals 5. Flexibility for producers o Basic building blocks of product stewardship programs o Developed by PSI in 2001 o Endorsements: National League of Cities, Environmental Council of States, Solid Waste Association of North America, and many other organizations April 29, 2011 7 Examples of Product Stewardship • Government oversees the implementation of product stewardship laws. • Phone book industry offers the public the chance to opt‐out of receiving phone books. • Manufacturer removes toxic substance from product or manufacturing process. • Retailers collect products for recycling. • Rechargeable battery manufacturers provide collection boxes to recycle their product.* • Fluorescent lamp manufacturers implement recycling program in Maine.* April 29, 2011 8 Extended producer responsibility Extended Producer Responsibility (EPR), a central tenet of product stewardship, is a policy approach in which the producer’s responsibility for their product extends to the post‐consumer management of that product and its packaging.
    [Show full text]
  • Associate Member Companies As of October 15, 2012 A&D Medical
    Associate Member Companies as of October 15, 2012 A&D Medical ‐ LifeSource Acosta Sales and Marketing Company San Jose CA Brea CA http://www.LifeSourceOnline.com http://www.acosta.com Aaron Industries Inc. Actavis Clinton SC Morristown NJ http://www.aaronindustriesinc.com http://www.actavis.us Abbott Diabetes Care Active International, Inc. Alameda CA Pearl River NY http://www.abbottdiabetescare.com http://www.activeinternational.com Abbott Medical Optics, Inc. Aderans Hair Goods Lake Forest CA Beverly Hills CA http://www.amo‐inc.com http://www.reneofparis.com Abbott Nutrition ADFLOW Health Networks Columbus OH Doylestown PA http://www.ross.com http://www.adflownetworks.com Abbott ‐ Pharmaceutical Products Division Adheris, Inc. Abbott Park IL Burlington MA http://www.abbott.com http://www.adheris.com Absolute AR Advance Sales Group, Inc. Fort Worth TX Commerce CA http://www.pdxinc.com http://www.advancesalesgroup.com Accera, Inc. Advanced Beauty, Inc. Broomfield CO Dallas TX http://www.accerapharma.com http://www.bodycology.us Accord Healthcare Advanced Marketing & Sales, Inc. Durham NC Vernon Hills IL http://accord‐healthcare.com http://www.amsrep.com Acon Laboratories Inc. Advanced Vision Research San Diego CA Lake Forest IL http://www.aconlabs.com http://www.theratears.com Associate Member Companies as of October 15, 2012 Advantage Consumer Healthcare LLC Alex Orthopedic, Inc. Pittsburgh PA Grand Prairie TX http://www.advantagechc.com http://www.alexorthopedic.com Advantage Sales and Marketing The Alkalol Company Irvine CA Boston MA http://www.asmnet.com http://www.alkalolcompany.com Adwin USA, Inc., Dba COHBE Allergan Inc. Carson CA Irvine CA http://www.cohbe.com http://www.allergan.com Affinnova Allison Medical Inc.
    [Show full text]
  • American Foundation for Pharmaceutical Education Box: 8
    Ronald Reagan Presidential Library Digital Library Collections This is a PDF of a folder from our textual collections. Collection: Turner, Carlton E.: Files Folder Title: American Foundation for Pharmaceutical Education Box: 8 To see more digitized collections visit: https://reaganlibrary.gov/archives/digital-library To see all Ronald Reagan Presidential Library inventories visit: https://reaganlibrary.gov/document-collection Contact a reference archivist at: [email protected] Citation Guidelines: https://reaganlibrary.gov/citing National Archives Catalogue: https://catalog.archives.gov/ .. i ! f;c~~~ I I ,J I American Foundation For Pharmaceutical Education I OIRECTOF)S RADBURN PLAZA BUILDING 14-25 PLAZA ROAD, FAIR LAWN, N.J. 07410 Ronald J. Brenner. Ph.D. (201) 791-5192 INCORPORATED 1942 Cytogen Corpnr~lion William H. Campbell. Ph .D. March 3, 1986 Unfrersity of Washington Herbert 5. Carlin OFFICERS The New York Hospital Peter G. Tombros. Chaimratt of Board Paul N. Clark Abbott Wboralories Ronald J. Brenner. Ph.D .. Via Clwimum of Board L. Jack R. Cole. Ph.D. Robert Hanson, Treasurer William F. Weigel. Coumel and S(•aetary Uni\·ersity of Ariwna Thomas M. Collins Carlton E. Turner, Ph.D. E. PresitJ,,,u SmithK/i11e Beckman Corpora/ion Richard Faust. Ph.D .. Herbert J. Conrad Deputy Assistant to the President Hoffmann-Lo Roche Inc. for Drug Abuse Policy John W. Culligan American Home Products Corporation The White House Angele C. D"Angelo Washington, DC 20001 St. John's University Robert A . Dube Owens-Illinois Dear Carlton, Frederick M. Eckel 1he University of Nonh Carolina George W. Eckelmann Thanks for your kind note just before the holidays ..
    [Show full text]
  • Discontinued Items Ct
    Discontinued Items ct Smith # Sz Description NDC/UPC Manufacturer 785006 1ct Paliperidone ER Tab 3mg 30ct 30591369330 Actavis/Teva 816686 1ct Irbesartan Tab 75mg 90ct 36233204190 Alembic Pharma 816652 1ct Irbesartan Tab 150mg 500ct 36233204271 Alembic Pharma 816660 1ct Irbesartan Tab 300mg 500ct 36233204371 Alembic Pharma 816678 1ct Irbesartan Tab 300mg 90ct 36233204390 Alembic Pharma 767558 1ct Valsartan Tab 40mg 90ct 36233204490 Alembic Pharma 767574 1ct Valsartan Tab 80mg 500ct 36233204571 Alembic Pharma 860023 1ct Econazole Nitrate Cream 1% 15gm 34778154372 Alvogen, Inc. 860031 1ct Econazole Nitrate Cream 1% 30gm 34778154373 Alvogen, Inc. 689729 1ct BV Pain Rel Caplets XS 2x100ct 34948334120 Basic Drugs 666172 1ct Dulco Gas Max Str Tangy Citrus 18ct 68142102611 Chattem Drug 195115 1ct Halls C Drops Sp/Mint Bag 30’s 31254662742 Dot Foods, Inc. 330019 1ct JJ Sport Tape 1 1/2x10yd 38137007902 Dot Foods, Inc. 381251 1ct Halls Defense Vit C S/Bry 20x9 Loz 31254605091 Dot Foods, Inc. 863753 1ct Fluocinonide Gel .05% 15gm 30713080315 G&W Labs 752238 1ct Aspirin Child Chew 81mg 3x36ct 30536100862 Major/Rugby 211169 1ct Reguloid S/Free Powder 10oz 30536188179 Major/Rugby 251884 1ct Lorazepam Tab .5mg 500ct 30378232105 Mylan Pharma 256982 1ct Lorazepam Tab 1mg 100ct 30378245701 Mylan Pharma 250662 1ct Lorazepam Tab 1mg 1000ct 30378245710 Mylan Pharma 259416 1ct Lorazepam Tab 2mg 100ct 30378277701 Mylan Pharma 246934 1ct Lorazepam Tab 2mg 500ct 30378277705 Mylan Pharma 740175 1ct Finasteride Tab 5mg 90ct 30378503677 Mylan Pharma 542753 1ct Levocetirizine/Dihydr Tab 5mg 300ct 34580259487 Perrigo Pharma 319574 1ct Colocort Enema 60ml 30574202001 Perrigo Pharma 687962 1ct Klor-Con M20 Tab ER 20MEQ 1000ct 36675819010 Sandoz Inc.
    [Show full text]
  • Product Stewardship Financing Models: a Look at the Post-Consumer Pharmaceutical Stewardship Association
    Product Stewardship Financing Models: A Look at the Post-Consumer Pharmaceutical Stewardship Association Type of Brand-owner funded take-back program (mandatory in BC and Manitoba). Program: Pharmaceuticals and natural health products, including prescription drugs, nonprescription Scope: medicines and natural health products such as herbal products, mineral and vitamin supplements (accepted in household quantities). In 1997, the B.C. Waste Management Act – Post Consumer Residual Stewardship, required all Status: brand-owners of pharmaceutical products to be responsible for their products’ end-of-life disposal. Starting in 2000, PCPSA began managing the stewardship plan with the Medications Return Program. The Recycling Regulation (B.C. Reg 449/2004) has now replaced the previous regulation. Overview Unused medications are a health and safety hazard when stored in patients’ homes. They can also damage the natural environment when incorrectly used or disposed of. The Post-Consumer Pharmaceutical Stewardship Association (PCPSA) is a non-profit organization that directly administers the Medications Return Program through funding from pharmaceutical and consumer health products members. PCPSA was established by the industry to comply with British Columbia’s Waste Management Act, a law intended to reduce the environmental and public health risks associated with consumer goods, including leftover medications. The act requires producers to establish a system to safely collect and dispose of the public’s unused medications. PCPSA has been successfully administering the program since 2000 and now represents over 140 pharmaceutical and consumer health products brand-owners (see the final page for a full listing). While these programs are regulated in British Columbia and Manitoba similar programs are run on a voluntary basis in other provinces and territories The program has been extremely successful in gaining the support and participation of community pharmacies.
    [Show full text]
  • Participating Vendor List October 2020
    Participating Vendor List October 2020 Contracted Vendor Additions Contracted Vendor Deletions Accord BioPharma, Inc. ACADIA Pharmaceuticals Inc. Adhezion Biomedical, LLC AdvancePierre Foods, Inc Automated HealthCare Solutions, LLC Allcare, Inc. Balance Vibration Technologies, Inc. Alliance Tech Medical, Inc. CitraPac, Inc. Bon Chef, Inc DuBois Chemicals, Inc. Bryton Corporation Exalt Printing Solutions, LLC Cardinal International Healthcare Information LLC Carter- Hoffmann Corp. Hershey Creamery Company Cosmed USA Kay Kare LLC Dinex International, Inc. Link America, LLC Faxitron Bioptics Merchant Advocate, LLC GE-OEC Medical Systems, Inc. Plastic Film, LLC Medcomflow SDI Labs Inc Medic Vision Imaging Solutions Ltd Sugar Foods Corporation National Recall Alert Center Sunfarm Food Service Pharm3r LLC Syracuse Banana Co., Inc. Sapheneia V. Marchese Inc. Stanley Elevator Company, Inc. Vari Sales Corporation T2 Biosystems Ziehm Imaging Inc Premier, Inc. 10/19/2020 Page 1 NOTE: -Contracted vendors are in plain text. -Vendors who have submitted bids are highlighted in YELLOW. Name Top Parent Name Ownership Stock Symbol Exchange 2G Medical, LLC. 2G Medical, LLC. Private 3 West Medical 3 West Medical Private 3M Company 3M Company Public MMM NYSE 3M Health Information Systems 3M Company Public MMM NYSE 3T Medical Systems LLC 3T Medical Systems LLC Private 410 Medical, Inc 410 Medical, Inc 4WEB Medical, Inc. 4WEB Medical, Inc. Private 6P International LLC 6P International LLC Private 7D Surgical 7D Surgical 8K Miles Software Services / Serj Solutions 8K Miles Software Services / Serj Solutions A M Communications Solutions Inc. A M Communications Solutions Inc. Private A Management Group A Management Group Private A&A Produce Co. A&A Produce Co. A&D Medical A&D Medical Private A&E Enterprises of Louisiana, LLC A&E Enterprises of Louisiana, LLC A&E Medical Corporation A&E Medical Corporation Private A-1 International, Inc.
    [Show full text]